Hormonal Therapy
The new medicine offered more benefits than Faslodex.
Combined with Verzenio, this new oral SERD may be a good option for advanced-stage breast cancer with an ESR1 mutation.
Protection varied by race and decreased with age.
The risk of breast cancer recurrence is higher in women with obesity treated with an aromatase inhibitor.
Ovarian suppression plus tamoxifen lowers recurrence risk.
Lowering medicine prices seems to be one of the best ways to help women stick to their hormonal therapy treatment plans after breast cancer surgery.
A CHEK2 mutation in younger women diagnosed with hormone receptor-positive breast cancer increases the risk of the cancer’s resistance to hormonal therapy treatment.
Taking Arimidex for 10 years after breast cancer surgery reduced recurrence risk, but didn’t improve overall survival.
The FDA has approved Orserdu, a new oral medicine to treat metastatic, estrogen receptor-positive, HER2-negative breast cancer with an ESR1 mutation.
In a randomized study, acupuncture eased joint pain caused by aromatase inhibitors in women diagnosed with early-stage, hormone receptor-positive breast cancer for 40 weeks.
Switching from an aromatase inhibitor and Ibrance to Faslodex and Ibrance as the first treatment for advanced-stage, estrogen receptor-positive breast cancer seemed to overcome treatment resistance caused by ESR1 mutations.
Stage I and stage II hormone receptor-positive breast cancer was more likely to shrink after hormonal therapy before surgery in Black women than in white women. But Black women had worse outcomes than white women if the breast cancer was a higher stage.
The latest results from the MONARCH 3 study show that adding Verzenio to an aromatase inhibitor improves overall survival by 12.6 months for advanced-stage, hormone receptor-positive, HER2-negative breast cancer.
Two years of hormonal therapy after surgery to remove estrogen receptor-positive breast cancer in pre-menopausal women helped reduce the risk of metastatic recurrence for 20 years.
Pre-menopausal women diagnosed with early-stage, hormone receptor-positive breast cancer who took an aromatase inhibitor along with ovarian suppression after surgery had a 3.2% lower risk of recurrence than women who took tamoxifen after surgery. Still, there was no difference in overall survival.
The risk of early-stage breast cancer coming back after 10 years is linked to a number of factors, including whether the cancer is estrogen receptor-positive.
Adding Kisqali to Femara as a first treatment for advanced-stage hormone-receptor-positive HER2-negative breast cancer in postmenopausal women improved overall survival by more than 1 year.
After taking tamoxifen for 2 to 3 years following surgery, postmenopausal women diagnosed with early-stage hormone-receptor-positive breast cancer had a better survival rate from taking 5 years of Femara rather than 2 to 3 years of Femara.
Survival rates were the same in postmenopausal women diagnosed with early-stage hormone-receptor-positive breast cancer whether they took a short treatment break during extended adjuvant hormonal therapy with Femara or took Femara continuously for 5 years after previously taking hormonal therapy for an initial 5 years.
After taking 5 years of hormonal therapy following surgery, postmenopausal women diagnosed with early-stage hormone-receptor-positive breast cancer got the same benefits from taking 2 more years of Arimidex as they did from taking 5 more years, with fewer side effects.
Women who report worse quality of life factors, such as poor physical well-being, poor social well-being, and a history of depression, are more likely to stop hormonal therapy early.
The latest results from the MONALEESA-3 study show that combining Kisqali plus Faslodex continues to offer better overall survival than Faslodex alone.
The latest results from the PALOMA-3 trial show that combining Ibrance and Faslodex continues to offer better overall survival than Faslodex alone.
Younger women diagnosed with hormone-receptor-positive breast cancer may skip or delay taking hormonal therapy medicine after surgery because they’re concerned about having children.